Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Impressive safety and efficacy for solid cancer patients followed by global clinical study plan
In the Phase 3 LIBRETTO-431 study, Retevmo more than doubled progression-free survival (PFS) compared to chemotherapy plus pembrolizumab in patients with advanced or metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)
Zilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertension
Dr Jitendra Singh launches API Chapter of AFMC, Pune; inaugurates the first annual conference of API-AFMS Continuing Medical Education (CME) on “Emerging trends in the practice of Medicine”
Patients Treated with ARIKAYCE plus macrolide-based background regimen had meaningfully larger improvements in QOL-B respiratory score
Subscribe To Our Newsletter & Stay Updated
